Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

COX-2 inhibitors from Merck Frosst

Sep. 13, 1996

A new class of selective COX-2 inhibitors from Merck Frosst

Sep. 13, 1996

CollaGenex and Istituto Gentili collaboration

Sep. 6, 1996

Superoxide ion production inhibitors from Sagami

Aug. 30, 1996

VLA-4 receptor-blocking drugs described by Zeneca

Aug. 30, 1996

Cyclooxygenase-2-inhibitors described by Japan Tobacco

Aug. 23, 1996

Alexion's C5 complement inhibitor effective in murine lupus model

Aug. 23, 1996

Cyclooxygenase-2 inhibitors from Merck Frosst

Aug. 23, 1996

Hyanalgese-D demonstrates negative efficacy in U.S. phase III trial

Aug. 23, 1996

KF-20444: Kyowa Hakko's novel antirheumatic agent

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 1, 2026.
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...